Part B Reimbursement: OIG Flags $66.3 Million in Improper Urine Specimen Validity Test Payments

These are tense times for providers of urine drug tests for Medicare and Medicaid patients. And on Feb. 20, the hot seat got even hotter with the issuance of a new OIG report saying CMS made $66.3 million worth of improper payments for specimen validity tests billed in combination with urine drug tests. Here’s an…